靶向SOS1的抗肿瘤小分子抑制剂研究进展
Research Progress of Antitumor Small Molecule Inhibitor Targeting SOS1
DOI: 10.12677/WJCR.2023.132014, PDF,   
作者: 黄景坤, 王 卉, 朱 雍：中国药科大学理学院，江苏 南京
关键词: SOS1；RAS；抗肿瘤；抑制剂；SOS1； RAS； Anti-Cancer； Inhibitor
摘要: 大鼠肉瘤(rat sarcoma, RAS)是人类癌症中最常发生突变的癌基因，约占所有人类癌症突变的30%。RAS基因与胞内多条控制增殖、分化等生理过程的通路相关。SOS1 (son of sevenless 1)作为RAS信号通路中的中心节点，可通过蛋白–蛋白相互作用激活RAS蛋白，因此SOS1小分子抑制剂为治疗RAS依赖性癌症提供机遇。最近一些文献和专利文件已经证明了其治疗RAS突变驱动型癌症的潜力，通过对SOS1蛋白及其小分子抑制剂进行总结，为其进一步研究和应用提供参考。
Abstract: Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, accounting for approximately 30% of all human cancer mutations. RAS gene is associated with several intracellular pathways which control proliferation, differentiation and other physiological processes. As a central node in RAS signaling pathway, SOS1 (son of sevenless 1) can activate RAS proteins through protein-protein interaction, thus explaining that SOS1 small molecule inhibitors offer an opportunity to treat RAS-dependent cancers. Its potential in the treatment of RAS mutation-driven cancers has been demonstrated in recent literature and patent documents, and the structure and indications of these SOS1 small molecule inhibitors are summarized to provide reference for further research and application.
文章引用：黄景坤, 王卉, 朱雍. 靶向SOS1的抗肿瘤小分子抑制剂研究进展[J]. 世界肿瘤研究, 2023, 13(2): 97-105. https://doi.org/10.12677/WJCR.2023.132014

参考文献

[1] Cherfils, J. and Zeghouf, M. (2013) Regulation of Small GTPases by GEFs, GAPs and GDIs. Physiologjcal Reviews, 93, 269-309.
[Google Scholar] [CrossRef] [PubMed]
[2] Bos, J.L., Rehmann, H. and Wittinghofer, A. (2007) GEFs and GAPs: Critical Elements in the Control of Small G Proteins. Cell, 129, 865-877.
[Google Scholar] [CrossRef] [PubMed]
[3] Buday, L. and Downward, J. (2008) Many Faces of Ras Activation. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1786, 178-187.
[Google Scholar] [CrossRef] [PubMed]
[4] Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D.M., Dai, S., Shokat, K.M. and Suga, H. (2020) GTP-State-Selective Cyclic Peptide Ligands of K-Ras (G12D) Block Its Interaction with Raf. ACS Central Science, 6, 1753-1761.
[Google Scholar] [CrossRef] [PubMed]
[5] Hillig, R.C. and Bader, N. (2022) Chapter Six: Targeting RAS on Cogenesis with SOS1 Inhibitors. In: O’Bryan, J.P. and Piazza, G.A., Eds., Advances in Cancer Research, Vol. 153, Academic Press, Cambridge, 169-203.
[Google Scholar] [CrossRef] [PubMed]
[6] Hoang, H.M., Umutesi, H.G. and Heo, J. (2021) Allosteric Autoactivation of SOS and Its Kinetic Mechanism. Small GTPases, 12, 44-59.
[Google Scholar] [CrossRef] [PubMed]
[7] Bandaru, P., Kondo, Y. and Kuriyan, J. (2019) The Interdependent Activation of Son-of-Sevenless and Ras. Cold Spring Harbor Perspectives in Medicine, 9, 1-14.
[Google Scholar] [CrossRef] [PubMed]
[8] Lee, Y.K., Low-Nam, S.T., Chung, J.K., Hansen, S.D., Lam, H.Y.M., Alvarez, S. and Groves, J.T. (2017) Mechanism of SOS PR-Domain Autoinhibition Revealed by Single-Molecule Assays on Native Protein from Lysate. Nature Communications, 8, Article No. 15061.
[Google Scholar] [CrossRef] [PubMed]
[9] Toma-Fukai, S. and Shimizu, T. (2019) Structural Insights into the Regulation Mechanism of Small GTPases by GEFs. Molecules, 24, Article 3308.
[Google Scholar] [CrossRef] [PubMed]
[10] Gureasko, J., Kuchment, O., Makino, D.L., Sondermann, H., Bar-Sagi, D. and Kuriyan, J. (2010) Role of the Histone Domain in the Autoinhibition and Activation of the Ras Activator Son of Sevenless. PNAS, 107, 3430-3405.
[Google Scholar] [CrossRef] [PubMed]
[11] Zarich, N., Anta, B., Fernandez-Medarde, A., Ballester, A., de Lucas, M.P., Camara, A.B., Anta, B., Oliva, J.L., Rojas-Cabaneros, J.M. and Santos, E. (2019) The CSN3 Subunit of the COP9 Signalo Some Interacts with the HD Region of SOS1 Regulating Stability of this GEF Protein. Oncogenesis, 8, Article No. 2.
[Google Scholar] [CrossRef] [PubMed]
[12] Soisson, S.M., Nimnual A.S., Uy, M., Bar-Sagi, D. and Kuriyan, J. (1998) Crystal Structure of the Dbl and Pleckstrin Homology Domains from the Human Son of Sevenless Protein. Cell, 95, 259-268.
[Google Scholar] [CrossRef] 
[13] Gureasko, J., Galush, Boykevisch, W.J., Sondermann, S.H., Bar-Sagi, D., Groves, J.T. andKuriyan, J. (2008) Membrane-Dependent Signal Integration by the Ras Activator Son of Sevenless. Nature Structural & Molecular Biology, 15, 452-461.
[Google Scholar] [CrossRef] [PubMed]
[14] Yadav, K.K. and Bar-Sagi, D. (2010) Allosteric Gating of Son of Sevenless Activity by the Histone Domain. PNAS, 107, 3436-3440.
[Google Scholar] [CrossRef] [PubMed]
[15] Margarit, S.M., Sondermann, H., Hall, B.E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D. and Kuriyan, J. (2003) Structural Evidence for Feedback Activation by Ras∙GTP of the Ras-Specific Nucleotide Exchange Factor SOS. Cell, 112, 685-695.
[Google Scholar] [CrossRef] 
[16] Boriack-Sjodin, P.A., Margarit, S.M., Bar-Sagi, D. and Kuriyan, J. (1998) The Structural Basis of the Activation of Ras by SOS. Nature, 394, 337-343.
[Google Scholar] [CrossRef] [PubMed]
[17] Hall, B.E., Yang, S.S., Boriack-Sjodin, P.A., Kuriyan, J. and Bar-Sagi, D. (2001) Structure-Based Mutagenesis Reveals Distinct Functions for Ras Switch 1 and Switch 2 in SOS-Catalyzed Guanine Nucleotide Exchange. Journal of Biological Chemistry, 276, 27629-27637.
[Google Scholar] [CrossRef] 
[18] Vo, U., Vajpai, N., Flavell, L., Bobby, R., Breeze, A.L., Embrey, K.J. and Golovanov, A.P. (2016) Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (SOS) Using Site-Specific NMR Reporter Signals and Intrinsic Fluorescence. Journal of Biological Chemistry, 291, 1703-1718.
[Google Scholar] [CrossRef] 
[19] Freedman, T.S., Sondermann, H., Kuchment, O., Friedland, G.D., Kortemme, T. and Kuriyan, J. (2009) Differences in Flexibility Underlie Functional Differences in the Ras Activators Son of Sevenless and Ras Guanine Nucleotide Releasing Factor 1. Structure, 17, 41-53.
[Google Scholar] [CrossRef] [PubMed]
[20] Sondermann, H., Soisson, S.M., Boykevisch, S., Yang, S.S., Bar-Sagi, D. and Kuriyan, J. (2004) Structural Analysis of Autoinhibition in the Ras Activator Son of Sevenless. Cell, 119, 393-405.
[Google Scholar] [CrossRef] [PubMed]
[21] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel, A.R. (1995) PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-Activated Protein Kinase Kinase in Vitro and in Vivo. Journal of Biological Chemistry, 270, 27489-27494.
[Google Scholar] [CrossRef] [PubMed]
[22] Zarich, N., Oliva, J.L., Martinez, N., Jorge, R., Ballester, A., Gutierrez-Eisman, S., Garcia-Vargas, S. and Rojas, J.M. (2006) Grb2 Is a Negative Modulator of the Intrinsic Ras-GEF Activity of HSOS1. Molecular Biology of the Cell, 17, 3591-3597.
[Google Scholar] [CrossRef] [PubMed]
[23] Corbalán-García, S., Margarit, S.M., Galron,D., Yang, S.S. and Bar-Sagi, D. (1998) Regulation of SOS Activity by Intramolecular Interactions. Molecular and Cellular Biology, 18, 880-886.
[Google Scholar] [CrossRef] 
[24] Nimnual, A. and Bar-Sagi, D. (2002) The Two Hats of SOS. Science Signaling, 2002, epe36.
[Google Scholar] [CrossRef] [PubMed]
[25] Rojas, J.M., Oliva, J.L. and Santos, E. (2011) Mammalian Son of Sevenless Guanine Nucleotide Exchange Factors: Old Concepts and New Perspectives. Genes & Cancer, 2, 298-305.
[Google Scholar] [CrossRef] [PubMed]
[26] Pierre, S., Bats, A.S. and Coumoul, X. (2011) Understanding SOS (Son of Sevenless). Biochemical Pharmacology, 82, 1049-1056.
[Google Scholar] [CrossRef] [PubMed]
[27] Christensen, S.M., Tu, H.-L., Jun, J.E., Alvarez, S., Triplet, M.G., Iwig, J.S., Yadav, K.K., Bar-Sagi, D., Roose, J.P. and Groves, J.T. (2016) One-Way Membrane Trafficking of SOS in Receptor-Triggered Ras Activation. Nature Structural & Molecular Biology, 23, 838-846.
[Google Scholar] [CrossRef] [PubMed]
[28] Ambrogio, C. (2021) ES28.03 Mechanisms of Resistance to KRAS G12C Inhibitors. Journal of Thoracic Oncology, 16, S96.
[Google Scholar] [CrossRef] 
[29] Corbalan-Garcia, S., Yang, S.S., Degenhardt K.R. and Bar-Sagi D. (1996) Identification of the Mitogen-Activated Protein Kinase Phosphorylation Sites on Human SOS1 that Regulate Interaction with Grb2. Molecular and Cellular Biology, 16, 5674-5682.
[Google Scholar] [CrossRef] 
[30] Rozakis-Adcock, M., van der Geer, P., Mbamalu, G. and Pawson, T. (1995) MAP Kinase Phosphorylation of mSos1 Promotes Dissociation of mSos1-Shc and mSos1-EGF Receptor Complexes. Oncogene, 11, 1417-1426.
[31] Thompson, S.K., Buckl, A., Dossetter, A.G., Griffen, E. and Gill, A. (2021) Small Molecule Son of Sevenless 1 (SOS1) Inhibitors: A Review of the Patent Literature. Expert Opinion on Therapeutic Patents, 31, 1189-1204.
[Google Scholar] [CrossRef] [PubMed]
[32] Hillig, R.C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C.M., Werbeck, N.D., Briem, H., Boemer, U., Weiske, J., Badock, V., Mastouri, J., Petersen, K., Siemeister, G., Kahmann, J.D., Wegener, D., Bohnke, N., Eis, K., Graham, K., Wortmann, L., von Nussbaum, F. and Bader, B. (2019) Discovery of Potent SOS1 Inhibitors that Block RAS Activation via Disruption of the RAS-SOS1 Interaction. Proceedings of the National Academy of Sciences of the United States of America, 116, 2551-2560.
[Google Scholar] [CrossRef] [PubMed]
[33] Liceras-Boillos, P., Jimeno, D., Garcia-Navas, R., Lorenzo-Martin, L.F., Menacho-Marquez, M., Segrelles, C., Gomez, C., Calzada, N., Fuentes-Mateos, R., Paramio, J.M., Bustelo, X.R., Baltanas, F.C. and Santos, E. (2018) Differential Role of the RasGEFs SOS1 and SOS2 in Mouse Skin Homeostasis and Carcinogenesis. Molecular and Cellular Biology, 38, 4538-4551.
[Google Scholar] [CrossRef] 
[34] Hofmann, M.H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J.R., Sanderson, M.P., Kessler, D., Trapani, F., Arnhof, H., Rumpel, K., Botesteanu, D.A., Ettmayer, P., Gerstberger, T., Kofink, C., Wunberg, T., Zoephel, A., Fu, S.C., Teh, J.L., Bottcher, J., Pototschnig, N., Schachinger, F., Schipany, K., Lieb, S., Vellano, C.P., O’Connell, J.C., Mendes, R.L., Moll, J., Petronczki, M., Heffernan, T.P., Pearson, M., McConnell, D.B. and Kraut, N. (2021) BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery, 11, 142-157.
[Google Scholar] [CrossRef] 
[35] 唐春雷, 范懿庆, 范为正, 姜虹羽, 等. 一种取代喹唑啉类化合物、药物组合物及其用途[P]. 中国专利, 115141188. 2022-10-04.
[36] He, H., Zhang, Y., Xu, J., Li, Y., Fang, H., Liu, Y. and Zhang, S. (2022) Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma. Journal of Medicinal Chemistry, 65, 13158-13171.
[Google Scholar] [CrossRef] [PubMed]
[37] Hofmann, M.H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A.A., Daniele, J.R., Waizenegger, I., Gmachl, M., Rudolph, D., Vellano, C.P., Marotti, M., Vucenovic, V., Heffernan, T.P., Marszalek, J.R., Petronczki, M.P. and Kraut, N. (2021) Abstract CT210: Trial in Process: Phase 1 Studies of BI 1701963, a SOS1: KRAS Inhibitor, in Combination with MEK Inhibitors, Irreversible KRASG12C Inhibitors or Irinotecan. Cancer Reaserch, 81, CT210.
[Google Scholar] [CrossRef] 
[38] Theard, P.L., Sheffels, E., Sealover, N.E., Linke, A.J., Pratico, D.J. and Kortum, R.L. (2020) Marked Synergy by Vertical inhibition of EGFR Signaling in NSCLC Spheroids Shows SOS1 Is a Therapeutic Target in EGFR-Mutated Cancer. eLife, 9, e58204.
[Google Scholar] [CrossRef] 

为你推荐